Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Sarepta Therapeutics announced it will resume shipping its gene therapy Elevidys for ambulatory Duchenne Muscular Dystrophy patients, following an FDA recommendation to lift a voluntary hold after a probe found a prior patient death unrelated to the therapy. However, the FDA maintains the hold for non-ambulatory patients as it continues to investigate two associated deaths, alongside another death linked to Sarepta's experimental SRP-9004, indicating persistent regulatory scrutiny and limiting the therapy's full market access.

Analysis

Sarepta Therapeutics has received a partial regulatory green light from the FDA, allowing it to resume shipments of its gene therapy Elevidys for the ambulatory Duchenne Muscular Dystrophy patient population. This development follows a probe that cleared the therapy in the death of one patient. However, this positive step is significantly tempered by the FDA's decision to maintain the hold on Elevidys for non-ambulatory patients, a key segment of the market, pending an investigation into two patient deaths within that group. Furthermore, the company faces broader scrutiny over its gene therapy platform, highlighted by a separate fatality linked to its experimental SRP-9004 therapy. This situation presents a mixed outlook, partially de-risking the commercial rollout for one patient cohort while simultaneously underscoring the substantial regulatory and safety overhang that continues to cloud the therapy's full market potential and the viability of Sarepta's broader pipeline.

Key Decisions for Investors

• Investors should recalibrate revenue forecasts for Elevidys to account for the continued exclusion of the non-ambulatory patient market, which represents a significant portion of the total addressable population.
• Closely monitor all communications from the FDA regarding the ongoing investigations, as any negative findings could materially impact Sarepta's stock and the long-term commercial viability of its gene therapy platform.
• Consider the heightened risk profile across Sarepta's entire gene therapy pipeline, as safety concerns now span multiple products, suggesting potential platform-level issues rather than an isolated incident.